Mini Review

Adverse drug reactions: classification, monitoring, and prevention

Russiachand Singh Heikham 1*

1 Department of Plant Science Raymond Building, 21111 Lakeshore Road Ste. Anne de Bellevue, Quebec H9X 3V9, Canada.

* Correspondence: heikham.singh@mail.mcgill.ca (R.S.H.)

Citation: Singh, R.S. Adverse drug reactions: classification, monitoring, and prevention. Glob. Jour. Bas. Sci. 2025, 1(9). 1-6.

Received: May 17, 2025

Revised: July 16, 2025

Accepted: July 26, 2025

Published: July 29, 2025

doi: 10.63454/jbs20000050

ISSN: 3049-3315

Volume 1; Issue 9

Download PDF file

Abstract: Adverse drug reactions (ADRs) represent a significant global public health challenge, contributing substantially to patient morbidity, mortality, and escalating healthcare expenditures. Defined as unintended, noxious responses to medications administered at standard therapeutic doses for prevention, diagnosis, or treatment, ADRs can range from mild discomfort to severe, life-threatening events. As therapeutic regimens become increasingly complex and polypharmacy becomes more common, the risk and prevalence of ADRs are rising correspondingly. This heightened risk underscores the critical necessity for their early detection, systematic monitoring, and proactive prevention as fundamental pillars of modern patient safety initiatives. Effective management of ADRs is contingent upon a clear understanding of their classification—often categorized by mechanism (Type A, predictable and dose-related; Type B, unpredictable and idiosyncratic)—and the underlying pharmacological or immunological pathways involved. This mini-review comprehensively addresses the clinical and economic burden of ADRs, elucidates their classification systems and pathophysiological mechanisms, and evaluates established and emerging methods for pharmacovigilance monitoring, such as spontaneous reporting systems and active surveillance. Furthermore, it outlines key preventive strategies, including medication reconciliation, therapeutic drug monitoring, pharmacogenetic testing, and enhanced patient education. The discussion emphasizes the indispensable role of robust pharmacovigilance systems and the proactive engagement of all healthcare professionals in mitigating this pervasive threat to therapeutic success and patient well-being.

Keywords: Adverse drug reactions; pharmacovigilance; drug safety; monitoring; prevention

1. Introduction

Medicines are foundational to modern healthcare, enabling the prevention, treatment, and management of a vast spectrum of diseases. However, no pharmaceutical intervention is entirely devoid of risk. The inherent duality of drug therapy is that agents capable of producing profound therapeutic benefits also carry the potential for harm. Adverse drug reactions (ADRs) exemplify this critical risk, representing one of the most significant, yet often preventable, threats to patient safety. Globally, ADRs are consistently ranked among the leading causes of hospital admissions, morbidity, and mortality, contributing substantially to prolonged hospital stays and escalating healthcare costs [1]. The World Health Organization (WHO) formally defines an ADR as “a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function” [2]. This definition distinguishes ADRs from consequences of medication errors, overdoses, or drug abuse. The burden of ADRs is intensifying due to several interrelated factors: the rise in polypharmacy, particularly among aging populations with multiple chronic conditions, which exponentially increases the risk of drug-drug interactions; widespread practices of self-medication without professional guidance; and the expanding use of high-risk therapeutic agents such as chemotherapeutics, anticoagulants, and novel biologics. Consequently, the systematic identification, rigorous monitoring, and proactive prevention of ADRs have transitioned from a clinical concern to a paramount public health priority, demanding coordinated efforts across healthcare systems, regulatory bodies, and all levels of clinical practice.

2. Burden and clinical impact of adverse drug reactions

Adverse drug reactions impose a substantial burden on global health systems, significantly contributing to patient harm and resource utilization. Epidemiological studies estimate that between 5% and 10% of all hospital admissions are directly attributable to ADRs, with a higher incidence observed among vulnerable populations such as the elderly and critically ill patients, who often have altered pharmacokinetics and multiple comorbidities [3]. Beyond initial hospitalization, ADRs are a leading cause of extended inpatient stays, increased morbidity, and preventable mortality. The economic impact is profound, stemming not only from the costs of prolonged hospitalization and complex medical investigations required to manage reactions but also from associated medico-legal expenses and long-term disability [4]. A critical insight from this data is that a significant proportion of these events, particularly predictable Type A reactions, are preventable. This underscores an urgent and systemic need for enhanced surveillance, the adoption of evidence-based, safer prescribing practices, and a cultural shift towards recognizing medication safety as a core component of clinical care.

3. Classification of adverse drug reactions

The systematic classification of adverse drug reactions (ADRs) is a fundamental scientific and clinical exercise that serves multiple critical purposes. It is far more than an academic taxonomy; it is a practical framework that provides essential structure to our understanding of drug-related harm. By organizing ADRs into coherent categories based on shared characteristics such as mechanism, predictability, and timing, classification allows clinicians, researchers, and regulators to speak a common language. This shared lexicon is vital for accurately communicating about the nature and severity of a reaction, facilitating more precise diagnoses, and enabling meaningful epidemiological comparisons across studies and populations (Figure 1). 

Ultimately, the primary utility of a robust classification system lies in its direct application to patient care and public health. A clear understanding of an ADR’s type directly informs clinical management. For instance, recognizing a reaction as a predictable, dose-dependent Type A event immediately suggests management strategies focused on dose adjustment or closer monitoring. In contrast, identifying an event as an unpredictable, idiosyncratic Type B reaction necessitates immediate drug discontinuation and investigation for possible immunological or genetic causes. From a public health and drug development perspective, classification is indispensable for guiding prevention strategies. It helps identify which reactions are amenable to prevention through better dosing regimens, patient selection, or pre-treatment screening (e.g., pharmacogenomic testing for certain Type B reactions). By elucidating the underlying etiology of different ADR categories, classification systems directly inform the design of safer drugs, more effective monitoring protocols, and targeted educational initiatives for healthcare professionals and patients, thereby forming the  conceptual bedrock for a systematic approach to medication safety. 

Figure 1. Adverse drug reactions (ADR): Classification, monitoring, and prevention.

3.1 Rawlins and Thompson classification
The most fundamental and widely adopted framework is the classification by Rawlins and Thompson, which distinguishes two primary categories [5]: 

  • Type A (Augmented) reactions: These are dose-dependent, pharmacologically predictable extensions of a drug’s known therapeutic effects. They are the most common type of ADR, accounting for approximately 80% of cases. Examples include hypoglycemia from insulin or bleeding from anticoagulants. Their predictability makes them largely preventable through careful dosing and monitoring.
  • Type B (Bizarre) reactions: These are idiosyncratic, dose-independent, and unrelated to the drug’s primary pharmacology. They are often immune-mediated or linked to individual patient genetics. Examples include anaphylaxis to penicillin or drug-induced Stevens-Johnson syndrome. Their unpredictability presents a greater diagnostic and preventive challenge.

3.2 Expanded classification
To encompass a broader range of drug-related harm, this binary system has been expanded to include several additional categories [6]:

  • Type C (Chronic): Reactions associated with long-term, continuous drug use (e.g., osteoporosis from corticosteroids).
  • Type D (Delayed): Effects that manifest months or years after exposure, such as carcinogenicity or teratogenicity.
  • Type E (End-of-use): Reactions occurring upon discontinuation of a drug (e.g., withdrawal syndromes from opioids or benzodiazepines).
  • Type F (Failure): Unexpected therapeutic failure, often resulting from drug interactions (e.g., reduced contraceptive efficacy with enzyme-inducing antibiotics) or the development of resistance.

4. Mechanisms of adverse drug reactions

The pathogenesis of ADRs is multifactorial, arising from complex interactions between drugs and biological systems. Mechanisms can be broadly grouped into:

  • Pharmacodynamic: An exaggerated but normal physiological response at the target site (Type A reactions).
  • Pharmacokinetic: Altered drug absorption, distribution, metabolism, or excretion, leading to abnormally high plasma concentrations.
  • Immunological: Hypersensitivity reactions ranging from mild rashes to severe anaphylaxis (Type B reactions).
  • Genetic: Inherited variations in drug-metabolizing enzymes (e.g., Cytochrome P450 isoforms), transporters, or drug targets can dramatically alter individual susceptibility. For instance, polymorphisms in genes like TPMT (thiopurine metabolism) or HLA alleles are strongly linked to specific, severe ADRs [7, 8].
  • Idiosyncratic: Mechanisms that are not yet fully understood, often involving unique patient-specific factors.

5. Monitoring of Adverse Drug Reactions

Effective and systematic monitoring of adverse drug reactions represents an indispensable public health function and the scientific backbone of post-marketing drug safety. Clinical trials, while essential for establishing initial efficacy and safety, are inherently limited in their ability to detect rare, delayed, or population-specific adverse events due to constrained sample sizes, short durations, and homogeneous participant groups. Therefore, ongoing pharmacovigilance is critical for characterizing the complete safety profile of a medicine throughout its lifecycle in the general population. This continuous process of surveillance transforms isolated clinical observations into actionable public health intelligence, enabling regulatory bodies, healthcare systems, and clinicians to make informed decisions that protect patient welfare.

5.1 Pharmacovigilance Systems
Pharmacovigilance is formally defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem [9]. It is a dynamic, multi-disciplinary field that extends beyond mere data collection to include causal assessment, risk-benefit analysis, and the implementation of risk minimization strategies. At the global level, the World Health Organization (WHO) Programme for International Drug Monitoring coordinates a collaborative network of national pharmacovigilance centers in over 170 member states. The program’s central database, VigiBase, is the world’s largest repository of individual case safety reports, containing millions of records contributed by these national centers. By aggregating data on a global scale, VigiBase utilizes sophisticated data mining techniques to detect subtle and rare safety “signals”—statistically significant associations between a drug and an adverse event that warrant further investigation. This international cooperation is vital for identifying risks that may be too infrequent or geographically dispersed to be recognized within any single country’s healthcare system [10].

5.2 Spontaneous reporting systems
Spontaneous reporting systems form the most widespread and foundational method of pharmacovigilance. In this passive surveillance model, healthcare professionals—and increasingly, patients through direct patient reporting programs—voluntarily submit reports of suspected ADRs to their national regulatory agency (e.g., the FDA’s MedWatch in the United States or the Yellow Card Scheme in the UK). The primary strength of this system is its broad, population-wide scope and cost-effectiveness, allowing for the early detection of unexpected and rare adverse events across diverse real-world settings. However, its utility is significantly hampered by chronic and severe underreporting, with estimates suggesting that over 90% of ADRs go unreported in many jurisdictions [11]. This underreporting stems from factors such as lack of time, uncertainty about causality, complacency with well-known side effects, and a perception that reporting is inconsequential. Consequently, while spontaneous reports are excellent for generating hypotheses about potential new risks, they cannot be used to calculate accurate incidence rates or conclusively establish causality.

5.3 Active surveillance methods
To address the quantitative and qualitative limitations of passive reporting, active surveillance methodologies are employed. These are prospective, systematic approaches designed to collect complete data on adverse events within a defined population. Key methods include:

  • Prescription Event Monitoring (PEM): In this approach, researchers identify a cohort of patients who have been prescribed a specific new drug. Questionnaires are then sent to their prescribers at regular intervals to record any clinical event that occurs, regardless of suspected drug causality, providing a clearer picture of the drug’s safety profile in routine practice.
  • Analysis of Large Healthcare Databases: This involves the retrospective or prospective mining of data from electronic health records, insurance claims databases, and disease registries. By applying analytical algorithms, researchers can compare event rates between users and non-users of a drug to identify potential associations, calculate true incidence, and assess risk factors.
    While these active methods yield more reliable and complete epidemiological data, they are substantially more resource-intensive, complex to administer, and often require sophisticated data infrastructure and analytical expertise [12].

5.4 Role of healthcare professionals
The effectiveness of any pharmacovigilance system is ultimately dependent on the vigilance and engagement of frontline healthcare professionals—physicians, pharmacists, and nurses. These clinicians are the primary “sentinels” for ADR detection, as they possess the clinical acumen necessary to distinguish a potential drug-related event from a progression of underlying disease. Their role is threefold: first, to maintain a high index of suspicion when assessing any new or worsening symptom in a medicated patient; second, to conduct a thorough causality assessment using standardized algorithms (e.g., the Naranjo scale) to determine the likelihood of a drug-related cause; and third, to ensure the complete and accurate documentation of the suspected reaction in the patient’s medical record and its subsequent formal reporting to the relevant pharmacovigilance authority. This last step is a critical professional responsibility, as each individual report contributes a vital piece of data to the collective safety evidence that informs clinical practice and protects future patients. Fostering a culture of safety where reporting is seen as a routine and valued component of clinical care is essential for strengthening national and global drug safety systems [13].

6. Prevention of adverse drug reactions

Mitigating the risk of adverse drug reactions requires a proactive, systematic, and multi-layered defense strategy that engages all stakeholders within the healthcare ecosystem, from prescribers and pharmacists to patients and health system administrators. This preventive model must operate at the levels of clinical decision-making, patient engagement, therapeutic monitoring, personalized medicine, and technological integration to address the diverse etiologies of ADRs effectively.

6.1 Rational prescribing
The cornerstone of ADR prevention lies in the principle of rational pharmacotherapy, a disciplined clinical approach that transcends mere drug selection. It is a holistic process that begins with a comprehensive patient assessment, ensuring an accurate diagnosis and a clear therapeutic goal. The prescriber must then deliberately select the most appropriate agent, considering not only its proven efficacy for the condition but also the patient’s unique context: age, renal and hepatic function, comorbidities, potential allergies, and concomitant medications. This is followed by careful calculation of an optimal dose and the establishment of a defined treatment duration. A critical and often overlooked component is the routine review and deprescribing of medications, actively minimizing unnecessary polypharmacy—a major independent risk factor for drug interactions and cumulative toxicity. Adherence to evidence-based guidelines, institutional formularies, and the WHO Essential Medicines List provides a structured framework to support these rational choices [14].

6.2 Patient education and communication
Effective prevention extends beyond the prescription pad to the patient themselves. Empowering patients through clear, accessible, and tailored education transforms them from passive recipients into active partners in medication safety. This involves transparent communication about the drug’s purpose, its common and serious potential side effects, and the critical importance of adherence to the prescribed regimen. Patients should be equipped to recognize early warning signs of an ADR and given clear guidance on when and how to seek medical help. This collaborative safety partnership not only improves adherence and therapeutic outcomes but also enables the early detection and intervention for adverse effects before they escalate into serious events. Effective communication builds trust and ensures that patient-reported outcomes become a valuable stream of safety data [15].

6.3 Therapeutic drug monitoring
For a specific subset of medications characterized by a narrow therapeutic index—where the margin between an effective dose and a toxic dose is small—reliance on standardized dosing is insufficient. Therapeutic Drug Monitoring is the standard of care for drugs such as digoxin, aminoglycosides, vancomycin, and many anticonvulsants and immunosuppressants. This practice involves the periodic measurement of a drug’s concentration in a patient’s blood (serum or plasma) at specific times. By interpreting these concentrations in the context of the patient’s clinical response, clinicians can scientifically individualize dosing regimens. TDM moves therapy from a population-based estimate to a patient-specific model, maximizing efficacy by ensuring therapeutic levels are reached while proactively preventing dose-related (Type A) toxicity. It is a direct application of pharmacokinetic principles to enhance safety [16].

6.4 Pharmacogenomics
Pharmacogenomics represents a paradigm shift in preventive medicine, moving from a reactive to a predictive model for ADRs. It studies how an individual’s unique genetic makeup influences their response to drugs. Specific genetic polymorphisms can alter the function of drug-metabolizing enzymes (e.g., CYP2D6, CYP2C19), drug transporters, or drug targets, leading to drastically different rates of drug activation, clearance, or receptor binding. By integrating pre-emptive or point-of-care genetic testing into clinical workflows, clinicians can identify patients with high-risk genetic profiles before a prescription is written. For example, testing for HLA-B *57:01* can prevent abacavir hypersensitivity, and testing for TPMT variants can guide safe thiopurine dosing in leukemia and autoimmune diseases. This allows for therapy to be tailored from the outset—by choosing an alternative drug or adjusting the initial dose—thereby preventing severe, often life-threatening, idiosyncratic (Type B) reactions and optimizing therapeutic efficacy [17].

6.5 Use of technology
Digital health technologies provide a critical, scalable safety net to catch errors before they reach the patient. Modern Electronic Health Records (EHRs) integrated with Clinical Decision Support Systems (CDSS) represent a powerful tool for ADR prevention. These systems can be programmed to perform real-time checks at the point of prescribing and dispensing. Alerts can flag known patient drug allergies, contraindications based on diagnosis or laboratory values (e.g., prescribing metformin in renal failure), and potentially dangerous drug-drug or drug-disease interactions. More advanced systems may incorporate dosing guidance based on renal function or provide reminders for necessary monitoring. By providing this contextual, evidence-based information instantly, technology reduces cognitive load on clinicians, helps standardize care according to guidelines, and intercepts a significant proportion of preventable prescribing errors that could lead to ADRs. Furthermore, EHR data analytics can facilitate active pharmacovigilance and population health management [18].

Significant barriers persist, particularly in resource-limited settings. These include pervasive underreporting due to lack of time, awareness, or perceived utility; insufficient training in pharmacovigilance among healthcare workers; and fragmented health information systems that impede effective surveillance [19]. Advancing ADR management will depend on strengthening pharmacovigilance infrastructure globally, harnessing artificial intelligence to analyze complex datasets for novel safety signals, mainstreaming pharmacogenomic testing into routine care, and embedding robust medication safety curricula into the lifelong education of all healthcare professionals [20].

7. Conclusion

Adverse drug reactions remain a pervasive threat to patient safety and a major driver of healthcare costs. A systematic understanding of their classification and mechanisms provides the necessary foundation for effective action. Mitigating their burden requires a concerted, proactive strategy centered on evidence-based rational prescribing, empowered patient engagement, robust national and international pharmacovigilance, and the strategic integration of genetic and digital technologies. By prioritizing these measures, healthcare systems can significantly improve therapeutic outcomes and enhance the overall safety profile of indispensable pharmaceutical interventions.

Author Contributions: Conceptualisation, R.S.H.; software, R.S.H.; investigation, R.S.H.;  writing—original draft preparation, R.S.H.; writing—review and editing, R.S.H.; visualisation, R.S.H.; supervision, R.S.H.; project administration, R.S.H. The author has read and agreed to the published version of the manuscript.

Funding: Not applicable.

Acknowledgments: We are grateful to Department of Plant Science Raymond Building, 21111 Lakeshore Road Ste. Anne de Bellevue, Quebec H9X 3V9, Canada for providing us all the facilities to carry out the entire work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the related data are supplied in this work or have been referenced properly.

References

  1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. British Medical Journal (BMJ). 2004;329(7456):15–19. doi:10.1136/bmj.329.7456.15
  2. World Health Organization. International Drug Monitoring: The Role of National Centres. World Health Organization; 1972.
  3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Journal of the American Medical Association (JAMA). 1998;279(15):1200–1205. doi:10.1001/jama.279.15.1200
  4. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. Journal of the American Medical Association (JAMA). 1997;277(4):301–306. doi:10.1001/jama.1997.03540280039031
  5. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of Adverse Drug Reactions. 3rd ed. Oxford University Press; 1977:44–56.
  6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000;356(9237):1255–1259. doi:10.1016/S0140-6736(00)02799-9
  7. Aronson JK. Medication errors: definitions and classification. British Journal of Clinical Pharmacology. 2009;67(6):599–604. doi:10.1111/j.1365-2125.2009.03415.x
  8. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends in Pharmacological Sciences. 2004;25(4):193–200. doi:10.1016/j.tips.2004.02.007
  9. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. World Health Organization; 2002.
  10. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal. 2008;42(5):409–419. doi:10.1177/009286150804200501
  11. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Safety. 2006;29(5):385–396. doi:10.2165/00002018-200629050-00003
  12. Mann RD, Andrews EB, eds. Pharmacovigilance. 2nd ed. John Wiley & Sons; 2007.
  13. van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Community pharmacists’ contribution to pharmacovigilance in the Netherlands. Pharmacy World & Science. 2004;26(6):313–317. doi:10.1007/s11096-004-2246-0
  14. World Health Organization. Promoting Rational Use of Medicines: Core Components. World Health Organization; 2002. (WHO/EDM/2002.3).
  15. Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A, et al. Concordance, Adherence and Compliance in Medicine Taking: A Conceptual Map and Research Priorities. National Institute for Health Research (NIHR) Service Delivery and Organisation programme. 2005. Report No.: SDO/52/2005.
  16. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean Journal of Internal Medicine. 2009;24(1):1–10. doi:10.3904/kjim.2009.24.1.1
  17. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817
  18. Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma’Luf N, et al. The impact of computerized physician order entry on medication error prevention. Journal of the American Medical Informatics Association. 1999;6(4):313–321. doi:10.1136/jamia.1999.00660313
  19. Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Drug Safety. 2016;39(4):335–345. doi:10.1007/s40264-015-0387-4
  20. Bate A, Hobbiger SF. Artificial Intelligence, Real-World Automation and the Safety of Medicines. Drug Safety. 2021;44(2):125–132. doi:10.1007/s40264-020-01001-7

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Global Journal of Basic Science and/or the editor(s). Global Journal of Basic Science and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Loading

Bibliography